- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01615835
EnSite NavX-Guided Coronary Sinus Mapping During CRT Implant (Bi-VNavX)
February 1, 2019 updated by: Abbott Medical Devices
Mapping in the Coronary Sinus During Implant of a Bi-Ventricular Implantable Cardioverter Defibrillator Utilizing the NavX Mapping System
Use of the EnSite NavX system to map the coronary vasculature during CRT implant
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Objective(s):
To determine the feasibility of CS mapping with NavX during Biventricular Implantable Cardioverter Defibrillator (BiV ICD) implantation.
Inclusion Criteria:
- Subject is between the age of 18 and 75 years
- Subject is willing and able to sign a study specific informed consent
- Subject is able to fulfill study requirements
- Meet the conventional criteria for implant of a BiV ICD, including; LVEF of ≤35%, QRS ≥ 120 ms and NYHA III-IV
- Have persistent CHF symptoms despite contemporary CHF medical therapy
- Stable and optimal medical therapy (stability is no changes in past 3 months).
- Documented history of ischemic or non-ischemic cardiomyopathy.
Exclusion Criteria:
- Have any standard device exclusions including tricuspid valve prosthesis/ replacement.
- Have a positive urine or serum pregnancy test (if female and of childbearing potential)
- Be currently participating in an IDE or IND study.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Medical College of Georgia
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 71 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meet criteria for CRT implant including EF<35%, QRS>120ms, NYHA class III or IV
- Persistent CHF symptoms despite optimization
- Stable/optimal medical therapy
- History of ischemic or non-ischemic cardiomyopathy
Exclusion Criteria:
- Any standard device exclusion including TVR
- Positive pregnancy test
- Currently participating in IDE/IND study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Determine feasibility of CS mapping with EnSite NavX during CRT implant
Time Frame: Procedural
|
Procedural
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Adam Berman, MD, Augusta University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
December 21, 2007
First Submitted That Met QC Criteria
June 6, 2012
First Posted (Estimate)
June 11, 2012
Study Record Updates
Last Update Posted (Actual)
February 4, 2019
Last Update Submitted That Met QC Criteria
February 1, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 067.3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
Clinical Trials on EnSite NavX System
-
Abbott Medical DevicesWithdrawn
-
Newmarket Electrophysiology Research Group IncMedtronicCompleted
-
Abbott Medical DevicesCompletedNon-paroxysmal Atrial Fibrillation | Left Atrial TachycardiaHong Kong, Australia, Italy, Germany, France
-
Rabin Medical CenterWithdrawn
-
Algenis SpACovanceCompleted
-
Barts & The London NHS TrustCompletedAtrial FibrillationUnited Kingdom
-
Boston Children's HospitalCompletedSupraventricular TachycardiaUnited States
-
Abbott Medical DevicesRecruiting
-
Algenis SpACompletedBack Pain | Acute PainChile